Answers are grounded in this paper and cite their sources.
Cross-sectional study evaluates GLP-1 receptor agonist prevalence and misuse in people with eating disorders, suggesting critical health implications.
This cross-sectional study evaluates the prevalence of glucagon-like peptide-1 (GLP-1) receptor agonist use and misuse among people with eating disorders in the US.
No takes yet. Share an insight, caveat, or question.
Peiper et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: